Compare DHX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | IMUX |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.0M | 155.8M |
| IPO Year | 2007 | 2013 |
| Metric | DHX | IMUX |
|---|---|---|
| Price | $4.85 | $7.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $6.75 | ★ $43.09 |
| AVG Volume (30 Days) | 255.2K | ★ 385.8K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $127,826,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $47.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $0.51 |
| 52 Week High | $5.19 | $17.43 |
| Indicator | DHX | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 57.05 | 23.18 |
| Support Level | $4.54 | $0.78 |
| Resistance Level | $5.10 | $15.82 |
| Average True Range (ATR) | 0.20 | 0.65 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 57.69 | 3.43 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.